24/7 Wall Street
25 Mar 2026, 13:44 UTC · 25w ago
Verdict
Headline takes no side. We score ARWR +0.80 across five claims — strongly bullish.
+0.80strongly bullish
More positive than 86% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
Sarepta Therapeutics released positive Phase 1/2 preliminary data for two siRNA programs targeting FSHD1 and DM1, showing proof-of-concept and favorable tolerability.
So whatPositive clinical data for unmet medical needs typically triggers significant short-term rallies in biotech stocks, as seen by the 20% jump.
More positive than 96% of claims this week
Sarepta Therapeutics expects to achieve profitability and positive cash flow in 2026, supported by $801 million in cash at year-end 2025.
So whatA clear path to profitability reduces the risk of dilutive financing and improves the long-term valuation floor.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 84% of claims this week
Arrowhead Pharmaceuticals received a $200 million milestone payment from Sarepta tied to the DM1 program progression.
More positive than 76% of claims this week
The company reported a full-year 2025 GAAP EPS loss of $5.05 and a previous 33% quarterly revenue decline due to an ELEVIDYS safety suspension.
More negative than 73% of claims this week
The FDA CBER lead, Vinay Prasad, is departing, potentially altering regulatory postures for gene and cell therapies.
More negative than 63% of claims this week
Which stocks this story touches
More positive than 86% of ticker scores this week
Received a $200 million milestone payment from Sarepta tied to the progression of the DM1 program.
More positive than 74% of ticker scores this week
Stock rose 20% following positive preliminary clinical data from two siRNA programs targeting rare diseases.
More positive than 78% of relationship scores this week
[mutual] Sarepta Therapeutics exclusively licenses siRNA programs from Arrowhead Pharmaceuticals.
More positive than 36% of relationship scores this week
[a_to_b] Sarepta paid a $200 million milestone payment to Arrowhead Pharmaceuticals.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
1d ago
+18.1%
Price agrees with the score
$66.48 vs $56.27 close before publication (Mar 24) · not market-adjusted
ARWR chart →
